Lion's Q3 Revenues Fall 65 Percent, Losses Narrow
Lion Bioscience last week reported sharply reduced revenues "in line with expectations," as well as reduced losses for its third fiscal quarter, ending Dec. 31, 2004.
Total revenues for the quarter fell 65 percent to €2.2 million ($2.9 million) from €6.3 million during the same period a year ago.
Lion did not break out its R&D costs for the quarter.
The company nearly halved its net loss for the quarter to €3.2 million from €6.3 million during the same quarter last year.